Evidence map›Paper›PMID 31991090›Full record

ReviewAmerican journal of respiratory cell and molecular biology2020

Applications and Approaches for Three-Dimensional Precision-Cut Lung Slices. Disease Modeling and Drug Discovery.

Hani N Alsafadi, Franziska E Uhl, Ricardo H Pineda, Kolene E Bailey, Mauricio Rojas, Darcy E Wagner, Melanie Königshoff

Abstract readReview
In one paragraph

Review in American journal of respiratory cell and molecular biology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 103 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
103citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

103 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Preclinical models of COPD: a state of the art review.The European respiratory journal · 2026
    Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. A human airway-on-a-chip microphysiological system for modeling chlorine gas toxicity.Toxicological sciences : an official journal of the Society of Toxicology · 2026
    Article
  12. Review
  13. Article
  14. Article
  15. Endothelial Heterogeneity in Pulmonary Hypertension.Arteriosclerosis, thrombosis, and vascular biology · 2026
    Review
  16. Review
  17. Targeting the epithelium in pulmonary fibrosis.European respiratory review : an official journal of the European Respiratory Society · 2026
    Review
  18. The ribosomal landscape in influenza A virus infection: from molecular mechanisms to clinical relevance.European respiratory review : an official journal of the European Respiratory Society · 2026
    Review
  19. Article
  20. Article

43 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Hani N AlsafadiLung Bioengineering and Regeneration, Department of Experimental Medical Science.ORCID 0000-0002-1186-2517
Franziska E UhlWallenberg Center for Molecular Medicine.ORCID 0000-0002-0641-4162
Ricardo H PinedaDivision of Pulmonary Sciences and Critical Care Medicine, Department of Medicine, University of Colorado Denver, Aurora, Colorado; and.
Kolene E BaileyDivision of Pulmonary Sciences and Critical Care Medicine, Department of Medicine, University of Colorado Denver, Aurora, Colorado; and.
Mauricio RojasDivision of Respiratory, Allergy and Critical Care Medicine, The Dorothy P. and Richard P. Simmons Center for Interstitial Lung Disease, University of Pittsburgh, Pittsburgh, Pennsylvania.
Darcy E WagnerLung Bioengineering and Regeneration, Department of Experimental Medical Science.ORCID 0000-0003-3794-1309
Melanie KönigshoffHelmholtz Zentrum Munich, Lung Repair and Regeneration, Comprehensive Pneumology Center, Member of the German Center for Lung Research, Munich, Germany.ORCID 0000-0001-9414-5128

Funding

Translational studies for identifying and targeting novel pathways in systemic sclerosis pathogenesisP50AR060780 · NIAMS · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI LAFYATIS, ROBERT A. · 2011 to 2021
$14.9M
Mapping Age-Related Changes in the LungU01HL145550 · NHLBI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI BENOS, PANAGIOTIS V, FINKEL, TOREN · 2019 to 2022
$2.4M
Non-canonical WNT signaling in emphysema and lung regenerationR01HL141380 · NHLBI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI KOENIGSHOFF, MELANIE · 2019 to 2022
$2.1M
Aging of Mesenchymal Stem Cells Missing Link in IPFR01HL123766 · NHLBI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI ROJAS, MAURICIO · 2015 to 2018
$1.9M
NHLBI NIH HHS R01 HL123766NHLBI NIH HHS R01 HL141380NHLBI NIH HHS U01 HL145550NIAMS NIH HHS P50 AR060780
6 · The paper itself

Abstract

Chronic lung diseases (CLDs), such as chronic obstructive pulmonary disease, interstitial lung disease, and lung cancer, are among the leading causes of morbidity globally and impose major health and financial burdens on patients and society. Effective treatments are scarce, and relevant human model systems to effectively study CLD pathomechanisms and thus discover and validate potential new targets and therapies are needed. Precision-cut lung slices (PCLS) from healthy and diseased human tissue represent one promising tool that can closely recapitulate the complexity of the lung's native environment, and recently, improved methodologies and accessibility to human tissue have led to an increased use of PCLS in CLD research. Here, we discuss approaches that use human PCLS to advance our understanding of CLD development, as well as drug discovery and validation for CLDs. PCLS enable investigators to study complex interactions among different cell types and the extracellular matrix in the native three-dimensional architecture of the lung. PCLS further allow for high-resolution (live) imaging of cellular functions in several dimensions. Importantly, PCLS can be derived from diseased lung tissue upon lung surgery or transplantation, thus allowing the study of CLDs in living human tissue. Moreover, CLDs can be modeled in PCLS derived from normal lung tissue to mimic the onset and progression of CLDs, complementing studies in end-stage diseased tissue. Altogether, PCLS are emerging as a remarkable tool to further bridge the gap between target identification and translation into clinical studies, and thus open novel avenues for future precision medicine approaches.

Indexed as

AnimalsDisease Models, AnimalDrug DiscoveryDrug Evaluation, PreclinicalHumansIdiopathic Pulmonary FibrosisLungLung DiseasesLung NeoplasmsMiceMicrotomyPulmonary Disease, Chronic ObstructiveSpecimen Handlingdrug discoveryex vivo lung diseasePCLStranslation

Identifiers

PMID31991090
PMCPMC7401444

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.